Výsledky vyhledávání - "R L, De Jager"

Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks

Autor: S, Sharma, N, Kemeny, G K, Schwartz, D, Kelsen, E, O'Reilly, D, Ilson, J, Coyle, R L, De Jager, M P, Ducharme, S, Kleban, E, Hollywood, L B, Saltz

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 7(12)

Exatecan mesylate (DX-8951f) is a topoisomerase I inhibitor that has increased solubility and antitumor activity compared with other topoisomerase I inhibitors. The purpose of this study was to establish a safe dose of DX-8951f given as a weekly 24-h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4ea50f09f6238189b232cb745caf4f82
https://pubmed.ncbi.nlm.nih.gov/11751488

Zobrazit plný text záznamu

Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(14)

PURPOSE: Preclinical studies have demonstrated that the adenovirus type 5 E1A gene is associated with antitumor activities by transcriptional repression of HER-2/neu and induction of apoptosis. Indeed, E1A gene therapy is known to induce regression o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d94b127eaaabe31634ab8a5d560e2b6
https://pubmed.ncbi.nlm.nih.gov/11689591

Zobrazit plný text záznamu

Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2

Autor: S A, Gulec, A N, Serafini, F L, Moffat, R D, Vargas-Cuba, G N, Sfakianakis, D, Franceschi, V Z, Crichton, R, Subramanian, J L, Klein, R L, De Jager

Publikováno v: Cancer research. 55

Radioimmunoscintigraphy (RIS) using human monoclonal antibodies offers the important clinical advantage of repeated imaging over murine monoclonal antibodies by eliminating the cross-species antibody response. This article reports a Phase I-II clinic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2b336e3e4217a168e77f0a2152433df1
https://pubmed.ncbi.nlm.nih.gov/7493345

Zobrazit plný text záznamu

Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy

Autor: T. Ciuleanu, B. A. Schaeffler, Y. Demidchik, M. Samarzjia, R. L. De Jager, S. V. Orlov, V. Beliakouski, D. L. Bentsion, M. Rancic, H. Breitz

Publikováno v: Journal of Clinical Oncology. 28:7002-7002

7002^ Background: Picoplatin is a new platinum compound designed to overcome platinum resistance and has demonstrated less neurotoxicity and nephrotoxicity than other platinum agents. The SPEAR study was designed to assess the efficacy and safety of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3d3bd9896ede89c4f556ae2983594726
https://doi.org/10.1200/jco.2010.28.15_suppl.7002

Zobrazit plný text záznamu

Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC)

Autor: R. L. De Jager, N. D. Lopatkin, L. Roman, Robert H. Earhart, P. Karlov, H. Breitz

Publikováno v: Journal of Clinical Oncology. 27:5140-5140

5140 Background: Picoplatin (Pico) was designed to overcome platinum resistance and has the potential for improved safety compared to other platinum agents. Previously, a PSA response rate of 25% was observed when Pico monotherapy was infused at 120

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ca5477666f8f47c60ba041dd7f1de3b
https://doi.org/10.1200/jco.2009.27.15_suppl.5140

Zobrazit plný text záznamu

Randomized phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to modified FOLFOX-6 as first-line therapy for colorectal cancer (CRC)

Autor: R. L. De Jager, Robert H. Earhart, S. Cheporov, Oleg Gladkov, M. Biakhov, H. Breitz

Publikováno v: Journal of Clinical Oncology. 27:4026-4026

4026 Background: Picoplatin (Pico) was designed to overcome platinum resistance and has the potential for improved safety compared to other platinum agents. FOLFOX (5-FU, LV, oxaliplatin [oxali]) treatment for advanced CRC has dose-limiting oxali- re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::205a63698d798c5efc8f239dce3af9e1
https://doi.org/10.1200/jco.2009.27.15_suppl.4026

Zobrazit plný text záznamu

Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors

Autor: D. Toft, Francis Burrows, G. Timony, Charles Erlichman, Claire S. Padgett, R. L. De Jager, David S. Mendelson, Muhammad Wasif Saif, Tomislav Dragovich, D. D. Von Hoff

Publikováno v: Journal of Clinical Oncology. 24:10062-10062

10062 Background: 17-AAG is a benzoquinone ansamycin that binds to and inhibits the HSP90 family of molecular chaperones leading to the proteasomal degradation of client proteins critical in malignant cell proliferation and survival. We have undertak

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c4357b6fba24e33824802eec221bc7a1
https://doi.org/10.1200/jco.2006.24.18_suppl.10062

Zobrazit plný text záznamu

A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC)

Autor: Ghassan K. Abou-Alfa, E. M. O' Reilly, Herbert Hurwitz, S. G. Eckhardt, W. G. Harker, Manuel Modiano, Richard Letourneau, J. Ackerman, R. L. De Jager, Nerses Simon Tchekmedyian

Publikováno v: Memorial Sloan Kettering Cancer Center

4006 BACKGROUND: DX is a novel hexacyclic, water-soluble, topoisomerase-1 inhibitor. DX has single-agent and combination activity with GEM in APC (D'Adamo, et al. ASCO, 2001; O'Reilly, et al. ASCO, 2002). A multicenter, randomized phase III trial com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a476206d43593d9804d29d761562fe04
https://doi.org/10.1200/jco.2004.22.90140.4006

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání